These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27875356)

  • 21. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.
    Shale MJ; Seow CH; Coffin CS; Kaplan GG; Panaccione R; Ghosh S
    Aliment Pharmacol Ther; 2010 Jan; 31(1):20-34. PubMed ID: 19681818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Table: safety of drugs for IBD in pregnancy.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e116. PubMed ID: 30036355
    [No Abstract]   [Full Text] [Related]  

  • 23. Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.
    Bröms G; Granath F; Stephansson O; Kieler H
    Scand J Gastroenterol; 2016 Dec; 51(12):1462-1469. PubMed ID: 27739352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
    Wauters L; Billiet T; Papamichael K; Ballet V; Joniau S; Verschueren P; Silversmit G; Van Assche G; Vermeire S; Ferrante M
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):84-90. PubMed ID: 27603297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
    Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
    Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
    Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
    J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse events of IBD therapies.
    Scribano ML
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S210-1. PubMed ID: 18816669
    [No Abstract]   [Full Text] [Related]  

  • 28. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
    Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
    Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive biomarkers for cytomegalovirus reactivation before and after immunosuppressive therapy: A single-institution retrospective long-term analysis of patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic syndrome (DRESS).
    Mizukawa Y; Kimishima M; Aoyama Y; Shiohara T
    Int J Infect Dis; 2020 Nov; 100():239-246. PubMed ID: 32891735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired Secretion of TNF-α by Monocytes Stimulated With EBV Peptides Associates With Infectious Complications After Kidney Transplantation.
    Vallin P; Désy O; Béland S; Bouchard-Boivin F; Houde I; De Serres SA
    Transplantation; 2018 Jun; 102(6):1005-1013. PubMed ID: 29470349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
    Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement.
    Ciccocioppo R; Racca F; Paolucci S; Campanini G; Pozzi L; Betti E; Riboni R; Vanoli A; Baldanti F; Corazza GR
    World J Gastroenterol; 2015 Feb; 21(6):1915-26. PubMed ID: 25684960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
    Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
    Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.
    Degasperi E; Caprioli F; El Sherif O; Back D; Colombo M; Aghemo A
    Expert Rev Gastroenterol Hepatol; 2016 Dec; 10(12):1373-1383. PubMed ID: 27718758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-TNFα therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation.
    Lapsia S; Koganti S; Spadaro S; Rajapakse R; Chawla A; Bhaduri-McIntosh S
    J Med Virol; 2016 Feb; 88(2):312-8. PubMed ID: 26307954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: A Meta-Analysis.
    Sarlos P; Szemes K; Hegyi P; Garami A; Szabo I; Illes A; Solymar M; Petervari E; Vincze A; Par G; Bajor J; Czimmer J; Huszar O; Varju P; Farkas N
    J Crohns Colitis; 2018 Mar; 12(4):489-498. PubMed ID: 29220427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
    Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
    JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative optimization of patients with inflammatory bowel disease undergoing gastrointestinal surgery: a systematic review.
    Zangenberg MS; Horesh N; Kopylov U; El-Hussuna A
    Int J Colorectal Dis; 2017 Dec; 32(12):1663-1676. PubMed ID: 29051981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?
    Papamichael K; Osterman MT; Siegel CA; Melmed GY; Dubinsky MC; Colombel JF; Hanauer SB; Cheifetz AS
    Gastroenterology; 2018 Mar; 154(4):1201-1202. PubMed ID: 29432749
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.